![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
PF Vonvoigtlander, RA Lahti and JH Ludens
U-50,488 (trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]- benzeneacetamide) displays analgesic actions in a variety (thermal, pressure and irritant) of assays in mice and rats. Naloxone and MR-2266 block this analgesic effect; thus it is mediated by opioid receptors. However, when compared to morphine analgesia, the naloxone and MR-2266 pA2 values for U-50,488 analgesia were much lower and higher, respectively. Likewise, although tolerance occurs to both morphine and U-50,488 analgesia, there was no cross-tolerance between these drugs, and U-50,488 does not cause morphine-type physical dependence. These observations suggest that different opioid receptors mediate the analgesic effects of morphine and U-50,488. The effects of U-50,488 appear to be mediated by the so-called kappa opioid receptor. In contrast to U-50,488, other reputed kappa opioid agonists displayed varying degrees of mu agonist (ketazocine and ethylketocyclazocine) and narcotic antagonist (bremazocine) activities. Thus U-50,488 is a more selective kappa agonist. This conclusion is further supported by binding studies; of all compounds tested, U-59,488 displacement of [3H]ethylketocyclazocine binding was uniquely not blocked by high concentrations of dihydromorphine. In addition to analgesia, this selective kappa agonist also causes opioid receptor-mediated sedation, diuresis and corticosteroid elevations. U-50,488 is a useful tool for studying contrasting kappa and mu opioid receptor-mediated effects.
This article has been cited by other articles:
|
|
 |
|
  W. Qi, K. K. Ebenezar, M. A. Samhan, and F. G. Smith Renal responses to the {kappa}-opioid-receptor agonist U-50488H in conscious lambs Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R162 - R168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, C. Chen, Y. Wang, and L.-Y. Liu-Chen Ligands Regulate Cell Surface Level of the Human {kappa} Opioid Receptor by Activation-Induced Down-Regulation and Pharmacological Chaperone-Mediated Enhancement: Differential Effects of Nonpeptide and Peptide Agonists J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 765 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Qi and F. G. Smith Modulation of systemic and renal haemodynamics by {kappa}-opioids in conscious lambs Exp Physiol, September 1, 2006; 91(5): 877 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Ansonoff, J. Zhang, T. Czyzyk, R. B. Rothman, J. Stewart, H. Xu, J. Zjwiony, D. J. Siebert, F. Yang, B. L. Roth, et al. Antinociceptive and Hypothermic Effects of Salvinorin A Are Abolished in a Novel Strain of {kappa}-Opioid Receptor-1 Knockout Mice J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 641 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chen, J.-G. Li, Y. Chen, P. Huang, Y. Wang, and L.-Y. Liu-Chen GEC1 Interacts with the {kappa} Opioid Receptor and Enhances Expression of the Receptor J. Biol. Chem., March 24, 2006; 281(12): 7983 - 7993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, K. Tang, S. Inan, D. Siebert, U. Holzgrabe, D. Y.W. Lee, P. Huang, J.-G. Li, A. Cowan, and L.-Y. Liu-Chen Comparison of Pharmacological Activities of Three Distinct {kappa} Ligands (Salvinorin A, TRK-820 and 3FLB) on {kappa} Opioid Receptors in Vitro and Their Antipruritic and Antinociceptive Activities in Vivo J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 220 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Recker and G. A. Higgins The Opioid Receptor Like-1 Receptor Agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one) Produces a Discriminative Stimulus in Rats Distinct from That of a {micro}, {kappa}, and {delta} Opioid Receptor Agonist Cue J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 652 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Huang, D. Steplock, E. J. Weinman, R. A. Hall, Z. Ding, J. Li, Y. Wang, and L.-Y. Liu-Chen {kappa} Opioid Receptor Interacts with Na+/H+-exchanger Regulatory Factor-1/Ezrin-Radixin-Moesin-binding Phosphoprotein-50 (NHERF-1/EBP50) to Stimulate Na+/H+ Exchange Independent of Gi/Go Proteins J. Biol. Chem., June 11, 2004; 279(24): 25002 - 25009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, J.-G. Li, P. Huang, W. Xu, and L.-Y. Liu-Chen Differential Effects of Agonists on Adenylyl Cyclase Superactivation Mediated by the {kappa} Opioid Receptors: Adenylyl Cyclase Superactivation Is Independent of Agonist-Induced Phosphorylation, Desensitization, Internalization, and Down-Regulation J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1127 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-G. Li, F. Zhang, X.-L. Jin, and L.-Y. Liu-Chen Differential Regulation of the Human kappa Opioid Receptor by Agonists: Etorphine and Levorphanol Reduced Dynorphin A- and U50,488H-Induced Internalization and Phosphorylation J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 531 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ventura, E. Zinellu, E. Maninchedda, and M. Maioli Dynorphin B Is an Agonist of Nuclear Opioid Receptors Coupling Nuclear Protein Kinase C Activation to the Transcription of Cardiogenic Genes in GTR1 Embryonic Stem Cells Circ. Res., April 4, 2003; 92(6): 623 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Armstead Role of Nociceptin/Orphanin FQ in the Physiologic and Pathologic Control of the Cerebral Circulation Experimental Biology and Medicine, December 1, 2002; 227(11): 957 - 968. [Abstract] [Full Text]
|
|
|
|
|
|
F. Zhang, J. Li, J.-G. Li, and L.-Y. Liu-Chen (-)U50,488H [(trans)-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide] Induces Internalization and Down-Regulation of the Human, but not the Rat, kappa -Opioid Receptor: Structural Basis for the Differential Regulation J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1184 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-G. Li, C. Chen, and L.-Y. Liu-Chen Ezrin-Radixin-Moesin-binding Phosphoprotein-50/Na+/H+ Exchanger Regulatory Factor (EBP50/NHERF) Blocks U50,488H-induced Down-regulation of the Human kappa Opioid Receptor by Enhancing Its Recycling Rate J. Biol. Chem., July 19, 2002; 277(30): 27545 - 27552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Li, J.-G. Li, C. Chen, F. Zhang, and L.-Y. Liu-Chen Molecular Basis of Differences in (-)(trans)-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidiny)-cyclohexyl]benzeneacetamide-Induced Desensitization and Phosphorylation between Human and Rat kappa -Opioid Receptors Expressed in Chinese Hamster Ovary Cells Mol. Pharmacol., January 1, 2002; 61(1): 73 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Szeto, Y. Soong, D. Wu, and J. Fasolo Resensitization of Blood Pressure Response to {micro}-Opioid Peptide Agonists After Acute Desensitization Anesth. Analg., September 1, 2001; 93(3): 581 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-J. Zhou, J.-M. Pei, G.-Y. Wang, S. Wu, W.-P. Wang, C.-H. Cho, and T.-M. Wong Inducible HSP70 mediates delayed cardioprotection via U-50488H pretreatment in rat ventricular myocytes Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H40 - H47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-Y. Wang, S. Wu, J.-M. Pei, X.-C. Yu, and T.-M. Wong {kappa}- but not {delta}-opioid receptors mediate effects of ischemic preconditioning on both infarct and arrhythmia in rats Am J Physiol Heart Circ Physiol, January 1, 2001; 280(1): H384 - H391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-G. Li, J. L. Benovic, and L.-Y. Liu-Chen Mechanisms of Agonist-Induced Down-Regulation of the Human kappa -Opioid Receptor: Internalization Is Required for Down-Regulation Mol. Pharmacol., October 1, 2000; 58(4): 795 - 801. [Abstract] [Full Text]
|
|
|
|
|
|
M. R. Brandt and C. P. France Chronic l-alpha -Acetylmethadol (LAAM) in Rhesus Monkeys: Tolerance and Cross-Tolerance to the Antinociceptive, Ventilatory, and Rate-Decreasing Effects of Opioids J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 168 - 178. [Abstract] [Full Text]
|
|
|
|
|
|
S. Sbrenna, M. Marti, M. Morari, G. Calo, R. Guerrini, L. Beani, and C. Bianchi L-Glutamate and gamma -Aminobutyric Acid Efflux from Rat Cerebrocortical Synaptosomes: Modulation by kappa - and {micro}- but Not delta - and Opioid Receptor Like-1 Receptors J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1365 - 1371. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. A. B. Slot and F. C. Colpaert Opiate States of Memory: Receptor Mechanisms J. Neurosci., December 1, 1999; 19(23): 10520 - 10529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wu, H. Y. Li, and T. M. Wong Cardioprotection of Preconditioning by Metabolic Inhibition in the Rat Ventricular Myocyte : Involvement of {kappa}-Opioid Receptor Circ. Res., June 25, 1999; 84(12): 1388 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-G. Li, L.-Y. Luo, J. G. Krupnick, J. L. Benovic, and L.-Y. Liu-Chen U50,488H-induced Internalization of the Human {kappa} Opioid Receptor Involves a {beta}-Arrestin- and Dynamin-dependent Mechanism. {kappa} RECEPTOR INTERNALIZATION IS NOT REQUIRED FOR MITOGEN-ACTIVATED PROTEIN KINASE ACTIVATION J. Biol. Chem., April 23, 1999; 274(17): 12087 - 12094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Muller, S. Hallermann, and D. Swandulla Opioidergic Modulation of Voltage-Activated K+ Currents in Magnocellular Neurons of the Supraoptic Nucleus in Rat J Neurophysiol, April 1, 1999; 81(4): 1617 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. D. Matthes, C. Smadja, O. Valverde, J.-L. Vonesch, A. S. Foutz, E. Boudinot, M. Denavit-Saubie, C. Severini, L. Negri, B. P. Roques, et al. Activity of the delta -Opioid Receptor Is Partially Reduced, Whereas Activity of the kappa -Receptor Is Maintained in Mice Lacking the µ-Receptor J. Neurosci., September 15, 1998; 18(18): 7285 - 7295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ventura, M. Maioli, G. Pintus, A. M. Posadino, and B. Tadolini Nuclear Opioid Receptors Activate Opioid Peptide Gene Transcription in Isolated Myocardial Nuclei J. Biol. Chem., May 29, 1998; 273(22): 13383 - 13386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Schlaepfer, E. C. Strain, B. D. Greenberg, K. L. Preston, E. Lancaster, G. E. Bigelow, P. E. Barta, and G. D. Pearlson Site of Opioid Action in the Human Brain: Mu and Kappa Agonists' Subjective and Cerebral Blood Flow Effects Am J Psychiatry, April 1, 1998; 155(4): 470 - 473. [Abstract] [Full Text]
|
|
|
|
|
|
J. Zhu, L.-Y. Luo, G.-F. Mao, B. Ashby, and L.-Y. Liu-Chen Agonist-Induced Desensitization and Down-regulation of the Human Kappa Opioid Receptor Expressed in Chinese Hamster Ovary Cells J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 28 - 36. [Abstract] [Full Text]
|
|
|
|
|
|
S. B. Bausch, T. M. Esteb, G. W. Terman, and C. Chavkin Administered and Endogenously Released Kappa Opioids Decrease Pilocarpine-Induced Seizures and Seizure-Induced Histopathology J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 1147 - 1155. [Abstract] [Full Text]
|
|
|
|
|
|
B. Kest, G. McLemore, B. Kao, and C. E. Inturrisi The Competitive alpha -Amino-3-Hydroxy-5-Methylisoxazole-4-Propionate Receptor Antagonist LY293558 Attenuates and Reverses Analgesic Tolerance to Morphine But Not to Delta or Kappa Opioids J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1249 - 1255. [Abstract] [Full Text]
|
|
|
|
|
|
J. Zhu, L.-Y. Luo, J.-G. Li, C. Chen, and L.-Y. Liu-Chen Activation of the Cloned Human Kappa Opioid Receptor by Agonists Enhances [35S]GTPgamma S Binding to Membranes: Determination of Potencies and Efficacies of Ligands J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 676 - 684. [Abstract] [Full Text]
|
|
|
|
|
|
R. E. Bartok and R. M. Craft Sex Differences in Opioid Antinociception J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 769 - 778. [Abstract] [Full Text]
|
|
|
|
|
|
C. G. a. C. Oberlander The Kappa Opioid Agonist Niravoline Decreases Brain Edema in the Mouse Middle Cerebral Artery Occlusion Model of Stroke J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 1 - 6. [Abstract] [Full Text]
|
|
|
|
|
|
S. S. Negus, N. K. Mello, P. S. Portoghese, and C.-E. Lin Effects of Kappa Opioids on Cocaine Self-Administration by Rhesus Monkeys J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 44 - 55. [Abstract] [Full Text]
|
|
|
|
|
|
K. W. Easterling and S. G. Holtzman Intracranial Self-Stimulation in Rats: Sensitization to an Opioid Antagonist Following Acute or Chronic Treatment with Mu Opioid Agonists, J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 188 - 199. [Abstract] [Full Text]
|
|
|
|
|
|
C. Ventura and G. Pintus Opioid Peptide Gene Expression in the Primary Hereditary Cardiomyopathy of the Syrian Hamster. III. AUTOCRINE STIMULATION OF PRODYNORPHIN GENE EXPRESSION BY DYNORPHIN B J. Biol. Chem., March 7, 1997; 272(10): 6699 - 6705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Abbruscato, S. A. Thomas, V. J. Hruby, and T. P. Davis Blood-Brain Barrier Permeability and Bioavailability of a Highly Potent and µ-Selective Opioid Receptor Antagonist, CTAP: Comparison with Morphine J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 402 - 409. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
